Creation and Validation of a Novel Sex-Specific Mortality Risk Score in LVAD Recipients
- PMID: 33764158
- PMCID: PMC8174331
- DOI: 10.1161/JAHA.120.020019
Creation and Validation of a Novel Sex-Specific Mortality Risk Score in LVAD Recipients
Abstract
Background Prior studies have shown that women have worse 3-month survival after receiving a left ventricular assist device compared with men. Currently used prognostic scores, including the Heartmate II Risk Score, do not account for the increased residual risk in women. We used the IMACS (International Society for Heart and Lung Transplantation Mechanically Assisted Circulatory Support) registry to create and validate a sex-specific risk score for early mortality in left ventricular assist device recipients. Methods and Results Adult patients with a continuous-flow LVAD from the IMACS registry were randomly divided into a derivation cohort (DC; n=9113; 21% female) and a validation cohort (VC; n=6074; 21% female). The IMACS Risk Score was developed in the DC to predict 3-month mortality, from preoperative candidate predictors selected using the Akaike information criterion, or significant sex × variable interaction. In the DC, age, cardiogenic shock at implantation, body mass index, blood urea nitrogen, bilirubin, hemoglobin, albumin, platelet count, left ventricular end-diastolic diameter, tricuspid regurgitation, dialysis, and major infection before implantation were retained as significant predictors of 3-month mortality. There was significant ischemic heart failure × sex and platelet count × sex interaction. For each quartile increase in IMACS risk score, men (odds ratio [OR], 1.86; 95% CI, 1.74-2.00; P<0.0001), and women (OR, 1.93; 95% CI, 1.47-2.59; P<0.0001) had higher odds of 3-month mortality. The IMACS risk score represented a significant improvement over Heartmate II Risk Score (IMACS risk score area under the receiver operating characteristic curve: men: DC, 0.71; 95% CI, 0.69-0.73; VC, 0.69; 95% CI, 0.66-0.72; women: DC, 0.73; 95% CI, 0.70-0.77; VC, 0.71 [95% CI, 0.66-0.76; P<0.01 for improvement in receiver operating characteristic) and provided excellent risk calibration in both sexes. Removal of sex-specific interaction terms resulted in significant loss of model fit. Conclusions A sex-specific risk score provides excellent risk prediction in LVAD recipients.
Keywords: left ventricular assist device; mortality; prognosis; risk score; sex disparity.
Conflict of interest statement
Dr. Cowger is a speaker for Abbott and Medtronic, consultant for Medtronic, and a member of the IMACS steering committee. Dr Kirklin is the director of the Data Coordinating Center for Society of Thoracic Surgeons INTERMACS. Dr Simon reports research support from Novartis, Aadi, and consultancy fees from Complexa, Actelion, and United Therapeutics. Dr Kormos is an Abbott employee. The remaining authors have no disclosures to report.
Figures

Similar articles
-
Accuracy of Seattle Heart Failure Model and HeartMate II Risk Score in Non-Inotrope-Dependent Advanced Heart Failure Patients: Insights From the ROADMAP Study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients).Circ Heart Fail. 2017 May;10(5):e003745. doi: 10.1161/CIRCHEARTFAILURE.116.003745. Circ Heart Fail. 2017. PMID: 28465311
-
Predicting survival in patients receiving continuous flow left ventricular assist devices: the HeartMate II risk score.J Am Coll Cardiol. 2013 Jan 22;61(3):313-21. doi: 10.1016/j.jacc.2012.09.055. Epub 2012 Dec 19. J Am Coll Cardiol. 2013. PMID: 23265328 Clinical Trial.
-
Pulmonary artery pulsatility index predicts right ventricular failure after left ventricular assist device implantation.J Heart Lung Transplant. 2016 Jan;35(1):67-73. doi: 10.1016/j.healun.2015.06.009. Epub 2015 Jun 17. J Heart Lung Transplant. 2016. PMID: 26212656
-
Derivation and Validation of a Novel Right-Sided Heart Failure Model After Implantation of Continuous Flow Left Ventricular Assist Devices: The EUROMACS (European Registry for Patients with Mechanical Circulatory Support) Right-Sided Heart Failure Risk Score.Circulation. 2018 Feb 27;137(9):891-906. doi: 10.1161/CIRCULATIONAHA.117.030543. Epub 2017 Aug 27. Circulation. 2018. PMID: 28847897
-
Pre-operative mortality risk assessment in patients with continuous-flow left ventricular assist devices: application of the HeartMate II risk score.J Heart Lung Transplant. 2014 Jul;33(7):675-81. doi: 10.1016/j.healun.2014.02.011. Epub 2014 Feb 14. J Heart Lung Transplant. 2014. PMID: 24726424
Cited by
-
Sex-Based Differences in Patients With Left Ventricular-Assisted Devices and Strokes.JACC Adv. 2024 Jan 11;3(2):100817. doi: 10.1016/j.jacadv.2023.100817. eCollection 2024 Feb. JACC Adv. 2024. PMID: 38939388 Free PMC article.
-
How to select a patient for LVAD.Indian J Thorac Cardiovasc Surg. 2023 Jul;39(Suppl 1):8-17. doi: 10.1007/s12055-022-01428-w. Epub 2022 Dec 15. Indian J Thorac Cardiovasc Surg. 2023. PMID: 37525705 Free PMC article. Review.
-
Advancing Quality Metrics for Durable Left Ventricular Assist Device Implant: Analysis of the Society of Thoracic Surgeons Intermacs Database.Ann Thorac Surg. 2022 May;113(5):1544-1551. doi: 10.1016/j.athoracsur.2022.01.031. Epub 2022 Feb 15. Ann Thorac Surg. 2022. PMID: 35176258 Free PMC article.
-
Special Considerations for Advanced Heart Failure Surgeries: Durable Left Ventricular Devices and Heart Transplantation.J Cardiovasc Dev Dis. 2024 Apr 15;11(4):119. doi: 10.3390/jcdd11040119. J Cardiovasc Dev Dis. 2024. PMID: 38667737 Free PMC article. Review.
-
Sex Differences in Recovery and Device Replacement After Left Ventricular Assist Device Implantation as Destination Therapy.J Am Heart Assoc. 2022 Mar;11(5):e023294. doi: 10.1161/JAHA.121.023294. Epub 2022 Feb 22. J Am Heart Assoc. 2022. PMID: 35191318 Free PMC article.
References
-
- Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, De Ferranti S, Després J‐P, Fullerton HJ, Howard VJ, et al. Executive summary: heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131:434–441. DOI: 10.1161/CIR.0000000000000152 - DOI - PubMed
-
- Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP; ADHERE Scientific Advisory Committee and Investigators . Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209–216. DOI: 10.1016/j.ahj.2004.08.005. - DOI - PubMed
-
- Fonarow GC, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, O'Connor CM, Pieper K, Sun JL, Yancy CW, et al. Influence of a performance‐improvement initiative on quality of care for patients hospitalized with heart failure: results of the organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE‐HF). Arch Intern Med. 2007;167:1493–1502. DOI: 10.1001/archinte.167.14.1493. - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical